Unknown PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT03423849

The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy

Prospective Randomized Controlled Study of the Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy

Sponsor: Zhiyong Yu

Conditions Breast Cancer Chemotherapy Effect Disease-free Survival

Interventions Capecitabine Cisplatin Gemcitabine Vinorelbine

Updated 6 times since 2018 Last updated: Feb 5, 2018 Started: Feb 8, 2018 Primary completion: Feb 8, 2020 Completion: Feb 8, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Breast Cancer and Chemotherapy Effect and is currently ongoing. Zhiyong Yu leads this study, which shows 6 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3
Mar 2020 — Jan 2021 [monthly]

Unknown Status PHASE2_PHASE3

Status: Not Yet Recruiting → Unknown Status
Jun 2018 — Mar 2020 [monthly]

Not Yet Recruiting PHASE2_PHASE3

▶ Show 1 earlier version

Mar 2018 — Jun 2018 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Feb 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zhiyong Yu

Data source: Shandong Cancer Hospital and Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.